Pfizer’s 2-dose vaccine is 94.8% effective. Or has an efficacy of 94.8%, whatever that means. Actually, the efficacy is only 51% after a single shot, according to their CDC briefing docs.
Hang on. STOP THE PRESS. A new “study” just determined that there was a statistical error in the previous study and that the first shot is in fact 92.6% effective.
WOW. So the second dose adds a whopping 2.6% efficacy?
And given that the side effects of the vaccine are much more significant after the second dose, why has Pfizer been peddling this second dose this whole time? A statistical error? Or was it because Moderna also discovered that it’s first dose also has a 92.1% efficacy? (It’s 2-dose efficacy is 94.5%)
The Moderna vaccine’s second dose adds an eerily similar(and minute) 2.4% efficacy.
Remind me again why we need both shots?
Cynics would probably say something about price gouging. That’s hard to believe of large pharma. No, the real reason is so we can achieve herd immunity, wipe the disease off the face of the earth, and nobody will ever get sick again with COVID. With such high efficacy and the Biden/Fauci aim to achieve herd immunity by fall, nobody will need treatment for COVID ever again.
Unless I’m wrong and Fauci is lying. I’ve been wrong before, but who has ever heard of a politician lying?
Or maybe he’s just doing the ostrich head in the sand thing and hasn’t noticed what’s going on at Pfizer.
The bean counters and immunologists at Pfizer seem to know something the rest of us don’t. The company has announced five trials to repurpose three drugs and trial a new one for the treatment of COVID-19.
- Ramipril sold under the brand name Altace among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease being tested to retarget for COVID treatment.
- Azithromycin used to treat a wide variety of bacterial infections, being tested in two studies to retarget for COVID treatment.
- PF-06650833 is a potent, selective and orally active inhibitor of interleukin-1 receptor used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas, being tested to retarget for COVID treatment.
- PF-07304814 a small molecule that targets the 3CL protease, an enzyme that coronaviruses use to assemble themselves and multiply, being tested for treatment of COVID.
In case you’re not aware of it, it can take billions of dollars to get a new drug to the market due to the four phases of trials they need to go through to win approval.
Except in the event of an emergency approval, such as the COVID vaccines. It wouldn’t be a stretch to discover that the FDA decides to issue emergency approval for patented big pharma drugs. The FDA temporarily issued emergency approval for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) (unpatented and cheap treatments) under pressure from the Trump administration, but then rescinded the approval.
Retargeting drugs (using drugs currently approved for another treatment) is cheaper because their safety has already been tested. But it’s still expensive and no pharmaceutical company is going to spend millions of dollars on expensive trials unless their risk adjusted payback is going to be significantly higher than several multiples of the trial.
And if the world (especially the US) achieves herd immunity, where is the payback?
I don’t know, but clearly someone at Pfizer has calculated that there will be an ample supply of COVID patients in the years to come.
P.
